Profile data is unavailable for this security.
About the company
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
- Revenue in USD (TTM)20.45m
- Net income in USD-104.56m
- Incorporated2015
- Employees171.00
- Location4D Molecular Therapeutics Inc5858 Horton Street #455, EmeryvilleEMERYVILLE 94608United StatesUSA
- Phone+1 (510) 505-2680
- Fax+1 (302) 655-5049
- Websitehttps://4dmoleculartherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prothena Corporation PLC | 89.25m | -172.40m | 1.21bn | 173.00 | -- | 2.41 | -- | 13.57 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Gyre Therapeutics Inc | 0.00 | -44.24m | 1.22bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
MannKind Corp | 224.60m | 8.49m | 1.25bn | 414.00 | 195.90 | -- | 92.93 | 5.57 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.29bn | 642.00 | 38.53 | 2.85 | 13.75 | 2.49 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
BioCryst Pharmaceuticals Inc | 355.40m | -208.59m | 1.30bn | 536.00 | -- | -- | -- | 3.65 | -1.07 | -1.07 | 1.81 | -2.31 | 0.727 | 0.1787 | 6.51 | 663,050.40 | -42.67 | -47.95 | -54.00 | -64.89 | 98.56 | 97.06 | -58.69 | -114.94 | 3.48 | -1.00 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.31bn | 171.00 | -- | 2.16 | -- | 64.06 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
Vir Biotechnology Inc | 79.60m | -539.44m | 1.32bn | 587.00 | -- | 0.8542 | -- | 16.63 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.34bn | 85.00 | -- | 2.19 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Belite Bio Inc (ADR) | 0.00 | -32.61m | 1.37bn | 20.00 | -- | 13.89 | -- | -- | -1.18 | -1.18 | 0.00 | 3.24 | 0.00 | -- | -- | 0.00 | -46.26 | -- | -46.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Akero Therapeutics Inc | 0.00 | -179.27m | 1.38bn | 58.00 | -- | 1.63 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.40bn | 297.00 | 232.04 | 3.24 | 129.13 | 4.65 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.41bn | 174.00 | -- | 4.76 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Xencor Inc | 162.18m | -133.36m | 1.42bn | 280.00 | -- | 2.32 | -- | 8.76 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Pacira Biosciences Inc | 681.75m | 70.47m | 1.43bn | 711.00 | 23.78 | 1.61 | 9.90 | 2.10 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.44bn | 244.00 | -- | 5.25 | -- | 33.95 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Holder | Shares | % Held |
---|---|---|
RA Capital Management LPas of 31 Mar 2024 | 5.05m | 9.87% |
BVF Partners LPas of 31 Mar 2024 | 3.92m | 7.67% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 3.18m | 6.22% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.16m | 6.17% |
Deep Track Capital LPas of 31 Mar 2024 | 3.03m | 5.93% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 2.96m | 5.79% |
Viking Global Investors LPas of 31 Mar 2024 | 2.93m | 5.74% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.28m | 4.46% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.18m | 4.26% |
Polar Capital LLPas of 31 Mar 2024 | 1.80m | 3.52% |